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Parathyroid hormone-related protein (PTHrP) and its receptor type 1 (PTH1R) are extensively expressed in the kidney, where they
are able tomodulate renal function. Renal PTHrP is known to be overexpressed in acute renal injury. Recently, we hypothesized that
PTHrP involvement in the mechanisms of renal injury might not be limited to conditions with predominant damage of the renal
tubulointerstitiumandmight be extended to glomerular diseases, such as diabetic nephropathy (DN). In experimentalDN, the over-
expression of both PTHrP and the PTH1R contributes to the development of renal hypertrophy as well as proteinuria. More recent
data have shown, for the first time, that PTHrP is upregulated in the kidney from patients with DN. Collectively, animal and human
studies have shown that PTHrP acts as an importantmediator of diabetic renal cell hypertrophy by amechanismwhich involves the
modulation of cell cycle regulatory proteins and TGF-𝛽1. Furthermore, angiotensin II (Ang II), a critical factor in the progression
of renal injury, appears to be responsible for PTHrP upregulation in these conditions. These findings provide novel insights into
the well-known protective effects of Ang II antagonists in renal diseases, paving the way for new therapeutic approaches.
1. Diabetic Nephropathy (DN)
End-stage renal failure due to diabetes mellitus, especially
type 2 diabetes, has been recently described as a medical
catastrophe of worldwide dimensions [1]. Diabetic nephropa-
thy (DN) is characterized by the development of proteinuria
and subsequent glomerulosclerosis, conditions which are
always preceded by renal cell hypertrophy [2]. Although
the diabetic kidney is extremely variable, from near normal
size to even small fibrotic kidney, renal enlargement due to
cellular hypertrophy and hyperplasia is an early feature of the
disease both in human and in experimental animal models,
especially in the absence of insulin treatment. Hypertrophy
of tubuloepithelial as well as glomerular cells, including both
visceral epithelial (podocytes) and mesangial cells, is an early
hallmark of diabetes renal involvement [3–5]. Over time,
glomerular cell hypertrophy might become a maladaptive
response leading to glomerulosclerosis.
Although the mechanisms by which high glucose (HG)
leads to renal cell hypertrophy are still not completely under-
stood, they appear to involve cell entry into the cell cycle—
associated with cyclin D
1
kinase activation early in G
1
—
and subsequent arrest at the G
1
/S interphase, implicating
inhibition or insufficient activation of cyclin E kinase, to
permit progression into S phase, and therefore, arrest of
cell cycle progression followed by an increase in cell protein
synthesis [6].
Recent studies have shown that HG-induced hypertrophy
involves an early activation of the renin angiotensin system,
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followed by an induction of TGF-𝛽
1
, which in turn activates
a cell cycle regulatory protein, the cyclin dependent kinase
inhibitor (CDKI) p27Kip1 [7–9]. The interaction of p27Kip1
with the cyclin E kinase has been implicated in the inhibition
of this late complex and thus the G
1
progression [10].
2. The Renal PTH/PTHrP System
In the adult kidney, both parathyroid hormone- (PTH-)
related protein (PTHrP) and the PTH1 receptor (PTH1R) are
abundant throughout the renal parenchyma, including the
intrarenal vasculature [11–13]. In the kidney, PTHrP appears
to modulate renal plasma flow and glomerular filtration
rate and induces proliferative effects on both glomerular
mesangial and tubuloepithelial cells [11–17]. Renal PTHrP is
overexpressed in several experimental nephropathies, includ-
ing acute renal injury, obstructive nephropathy, and a rat
model of tubulointerstitial scarring after protein overload,
associated with the development of proteinuria [12, 18]. The
recent development of a transgenic mouse model character-
ized by PTHrP overexpression in the renal proximal tubule
made it possible to explore the functional consequences of
chronic PTHrP overexpression in experimental models of
renal damage (reviewed in [19]). This novel approach has
provided valuable data which have helped to disclose the
true roles of PTHrP in the damaged kidney. The following
paragraphs describe the latest results in experimental as well
as in human DN.
3. PTHrP in Experimental DN
Recently, we hypothesized that PTHrP involvement in
the mechanisms of renal injury might not be limited
to conditions with predominant damage of the renal
tubulointerstitium and might be extended to glomerular
diseases, such as DN. Using an experimental model of
DN induced by streptozotocin (STZ) [20], we studied the
possible changes in the PTHrP/PTH1R system associated
with the outcome of this nephropathy, characterized by
an initial phase of renal hypertrophy at both tubular and
glomerular levels, followed by an increase in urinary albumin
excretion (UAE) (proteinuria) [21, 22]. DN was induced in
Swiss-CD1 (CD1) mice as well as in PTHrP-overexpressing
mice. In the diabetic CD-1 mice, a significant increase in
the expression of both PTHrP and PTH1R was observed,
at both glomerular and tubular levels, associated with the
development of an increase in the UAE [20]. On the other
hand, diabetic PTHrP-overexpressing mice, in comparison
to their control littermates, have increased renal hypertrophy,
a significantly higher UAE, and lower total plasma protein
levels. A significant association among the renal expression of
PTHrP, PTH1R, and UAE was found to occur in the diabetic
mice. Furthermore, there was a 6-fold increase in the risk of
developing proteinuria in those mice with the higher PTHrP
and PTH1R levels, according to the logistic regression analy-
sis [20]. It is interesting to mention that albeit the STZmodel
has limitations for assessing long-term histomorphological
changes in the diabetic kidney [21], the aforementioned
findings might have pathophysiological implications since
the amount of proteinuria is a reliable predictor of diabetic
nephropathy [22]. Thus, these studies indicate that the
renal PTHrP/PTH1R system is upregulated in STZ-induced
diabetic mice, where it appears to be involved in renal hyper-
trophy and adversely affects the outcome of DN.
More recently, the putative role of PTHrP in the hypertro-
phy of the diabetic kidney was explored. In this way Romero
et al. observed that PTHrP plays a key role in themechanisms
ofHG-induced podocyte hypertrophy. It is worthmentioning
that podocytes are thought to be terminally differentiated cell
and hence not able to regenerate in vivo. In these studies, HG-
induced podocyte hypertrophy was inhibited by the presence
of a specific PTHrP neutralizing antibody. Interestingly, in
this condition HG also failed to upregulate the expression of
the hypertrophy factor TGF-𝛽
1
[23].
Although PTHrP does not seem to affect podocyte
apoptosis, it was shown to be able to modulate the expression
of several positive as well as negative cell cycle regulatory
proteins. In this way, while PTHrP (1–36) was shown to
stimulate cyclin D
1
, thus promoting podocytes to enter into
G
1
, it also downregulates cyclin E, hence blocking the cell
cycle later in G
1
. Moreover, PTHrP is able to upregulate
the negative cell cycle regulatory protein p27Kip1 which
plays a key role in diabetic cell hypertrophy by preventing
activation of cyclin E activity and arresting the cell cycle
later in G
1
[4, 23]. Interestingly, Romero et al. [23] found
that the pharmacological blockade of the PTH1R inhibited
the p27Kip1 upregulation induced by both HG and AngII.
Taken together, these data suggest that PTHrPmight mediate
the hypertrophic signaling acting in an autocrine/intracrine
fashion through the PTH1R receptor.
To discern the mechanism involved in the stimulation
of p27Kip1 induced by both PTHrP and TGF-𝛽
1
, Romero
et al. [23] performed two experimental approaches. First,
they found that using a PTHrP siRNA inhibited the ability
of HG and AngII to stimulate the upregulation of p27Kip1,
albeit it could not prevent the TGF-𝛽
1
upregulation of this
protein. Secondly, on TGF-𝛽
1
siRNA transfected podocytes,
PTHrP (1–36) failed to induce both p27Kip1 overexpression
and hypertrophy, thus suggesting that TGF-𝛽
1
mediates both
p27Kip1 upregulation and the hypertrophy response induced
by PTHrP on HG conditions.
Interestingly, Romero et al. [23] observed that the glomer-
ular expression of both TGF-𝛽
1
and p27Kip1 are constitutively
upregulated in PTHrP-overexpressing mice, albeit the latter
was not accompanied by renal hypertrophy [24]. This result
seems plausible since the hypertrophic mechanism requires
the entry into the cell cycle and subsequent arrest at the
G
1
/S interphase. Several studies have demonstrated that in
glomerular mesangial cells grown in HG ambient, initially,
self-limited proliferation occurs due to generation of HG-
induced growth factors, followed by cell cycle arrest in the
G
1
due to the expression of factors that block the checkpoint
G
1
-S interphase and undergo cellular hypertrophy [4, 25–27].
Of considerable interest is the fact that previous studies on
PTHrP-overexpressing mice have revealed the constitutive
upregulation of various proinflammatory mediators [28],
including the vascular endothelial growth factor-1 [29]
Journal of Diabetes Research 3
without evidence of kidney damage in the absence of a renal
insult. In any case, these data strongly suggest that PTHrP
might participate in the upregulation of glomerular TGF-𝛽
1
and p27Kip1. Collectively, these results indicate that the renal
PTHrP/PTH1R system is upregulated in streptozotocin-
induced diabetes in mice and appears to be involved with
renal hypertrophy and adversely affects the outcome of DN.
4. PTHrP in Human DN
In order to extend our studies into human DN, we developed
two experimental approaches (30). We first assessed whether
PTHrPmight be upregulated in the kidney frompatientswith
DN. And secondly, we analyzed the potential role of PTHrP
in the mechanisms of HG-induced hypertrophy in another
glomerular cell line known to be affected in this condition,
such as human mesangial cells (HMC).
By using immunohistochemistry in kidney sections from
patients with clinical and histopathological diagnosis of
DN, we observed an intense PTHrP upregulation in both
glomerular and tubuloepithelial cells, including a remarkable
nuclear immunolocalization in the latter cells. Interestingly,
the kidneys of these patients displayed a similar pattern of
PTHrP immunolocalization to that previously observed in
a diabetic mouse model [23]. Although the human diabetic
kidney is extremely variable in size, renal enlargement due to
hypertrophy and hyperplasia is an early feature of the disease
as measured by several imaging techniques [1, 30]. Due to the
fact that kidney size measurement is not regularly assessed
in the clinical setting, this parameter was not available in
the studied human cohort. However, the fact that all of these
patients presented a pattern of PTHrP staining similar to that
observed in the mouse model referred to previously, together
with present in vitro data in HMC, strongly suggests that
PTHrP may be an important factor in the pathophysiology
of glomerular mesangial cell hypertrophy in diabetic patients
(Figure 1).
In vitro studies have established that prolonged exposure
of human as well as rodent MC to HG in the absence of
exogenous growth factors triggers hypertrophy after a brief
self-limited mitogenic effect [31]. We and other investigators
previously reported that the N-terminal fragment of PTHrP
is mitogenic for these cells [13, 16]. Our data herein show
that HG-induced HMC hypertrophy was associated with a
progressive increase in PTHrP protein expression between
24 and 72 h. Moreover, exogenous PTHrP (1–36) displays
an early (24 h) proliferative effect followed by a hypertrophy
response at 72 h. Thus, PTHrP seems to recapitulate the
proliferative as well as the hypertrophy response induced by
HG on cultured HMC (30).
In order to study the mechanism whereby PTHrP (1–36)
was able to switch its initialmitogenic stimulus into hypertro-
phy, we assessed the expression of several cell cycle regulatory
proteins known to modulate this cellular effect. Both HG and
PTHrP (1–36) were initially (24 h) shown to trigger HMC to
enter the cell cycle, associated with an increase of both cyclins
D1 and E and cdk2 activity. Later, at 72 h, only cyclin D1
remained increased, together with cyclin E/cdk2 inactivation.
In this sense, it is well accepted thatwhile cyclinDgoverns the
physical growth of the cell, cyclin E determines whether the
growth pattern of renal cells will be one of hyperplasia (cyclin
E upregulation) or hypertrophy (cyclin E downregulation)
[32].The cdk inhibitor p27Kip1 is also known to play a key role
in the mechanisms of HG-induced MC hypertrophy by reg-
ulating (inhibiting) the activity of the cyclin E/cdk2 complex
[33, 34]. Interestingly, we also show that PTHrP (1–36) was
able to upregulate p27Kip1 in a similar fashion and time frame
as HG medium. Collectively, our findings indicate that the
observed decrease in cyclin E/cdk2 complex kinase activity
elicited by either HG or PTHrP (1–36) related to HMChyper-
trophy is likely a consequence of both cyclin E downregula-
tion and p27Kip1 upregulation. In addition, these data strongly
suggest that HG and PTHrP (1–36) interact with a common
cellular pathway leading to hypertrophy in HMC (30).
The potential role of PTHrP on the mechanisms of HG-
induced HMC hypertrophy was further assessed by observ-
ing that antagonizing the PTHrP system abolished the latter,
together with reversal of the hypertrophy-related changes in
the cell cycle (30). As we previously observed in a mouse
podocyte cell line, we find that PTHrP is also able to stimulate
the protein expression of TGF-𝛽
1
and its type II receptor in
HMC, and a neutralizing TGF-𝛽
1
antibody abrogated HMC
hypertrophy induced by PTHrP (1–36). Moreover, blockade
of the PTHrP system abolished TGF-𝛽
1
upregulation but not
that of its type II receptor by HG in these cells. In this regard,
upregulation of the latter receptor has been shown to be
associatedwith increasedTGF-𝛽-mediated growth inhibition
[35], whereas its reduced expression contributes to the loss
of sensitivity to TGF-𝛽 and the increased proliferation of
some cancer cells [36, 37]. Therefore, it is likely that the
TGF-𝛽 system might also be activated, contributing to HMC
hypertrophy by a PTHrP-independent mechanism. In any
event, these findings indicate that TGF-𝛽1 is a downstream
mediator of PTHrP (1–36) to induce hypertrophy in HMCs,
as previously discussed in mouse podocytes [23].
5. Interaction between PTHrP and
Angiotensin II in the Damaged Kidney
The renin-angiotensin system is well known for playing an
important pathogenic role in the mechanisms of renal injury
[38, 39]. Local activation of components of this system,
including Ang II, in the kidney has shown to occur early in
various experimental models of ARF, for example, folic acid-
induced nephrotoxicity and ischemia/reperfusion [11, 39, 40].
Moreover, Ang II antagonists exert beneficial effects on renal
function in these models [39, 41, 42].
Recent data strongly suggest that PTHrP might be
involved in the mechanisms related to Ang II-induced renal
injury. Exogenously administered Ang II, via its type 1 (AT1)
receptor, increases PTHrP expression in glomerular and
tubular cells as well as in vascular smooth muscle cells both
in vivo and in vitro [43, 44]. Interestingly, a significant cor-
relation between PTHrP overexpression and tubular damage
and fibrosis was observed in the rat kidney after systemic
Ang II infusion [43]. Furthermore, in nephrotoxic ARF,
the improvement of renal function by Ang II antagonists
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Figure 1: Immunostaining for PTHrP in the kidney of patients with diabetic nephropathy. PTHrP was detected by using a goat 𝛼-PTHrP
antibody (Santa Cruz Biotechnology) in kidney tissue sections from patients with clinical and histological diagnosis of DN. (a) Section from
normal kidney showing PTHrP immunostaining restricted to the epithelial cells cytoplasm of convoluted renal tubules. (b, c) Kidney samples
from two diabetic patients with different degree of DN: one patient with moderate (b) or more severe (c) diabetic glomerulosclerosis. PTHrP
labelling was present in both the glomeruli and the tubuloepithelial cells. Original magnifications ×300.
was associated with inhibition of PTHrP overexpression
[38]. These aggregated data suggest that Ang II is a likely
candidate responsible for PTHrP overexpression, and this
might contribute to the deleterious effects of Ang II in the
damaged kidney. These findings could provide novel insights
into the well-known protective effects of Ang II antagonists
in renal diseases, possibly leading the way to new therapeutic
approaches.
6. Conclusion
Collectively, these results indicate that the renal PTHrP/
PTH1R system is upregulated in experimental as well human
diabetes, appears to be involved with renal hypertrophy, and
adversely affects the outcome of DN. PTHrP also participates
in the hypertrophic signalling triggered byHGon glomerular
cells. In this condition, AngII induces the upregulation
of PTHrP, which might induce the expression of TGF-𝛽
1
and p27Kip1. These findings provide new insights into the
protective effects of AngII antagonists in DN, paving the way
for new forms of intervention.
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